SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MedImmune
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dennis who wrote (242)12/17/2002 8:26:36 PM
From: Dennis   of 416
 
FDA panel backs limited approval for FluMist (MEDI) by Ted Griffith
A Food and Drug Administration advisory panel voted late Tuesday to recommend approval for MedImmune's nasal-spray flu vaccine for people aged 5 to 49. The panel concluded that the vaccine, called FluMist, was safe for people from 50 to 64, Reuters reported. But it found there wasn't enough evidence to prove the vaccine is effective in that age group. The FDA typically follows the recommendations of its panels, which are made up of medical experts. Shares of MedImmune (MEDI) were halted at $24.99.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News